NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. (“Zeo” or the “Company”) (NASDAQ: ZEO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Zeo and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On May 29, 2025, Zeo announced receipt of “a notice . . . from Nasdaq on May 22, 2025, notifying the Company that it is not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) because the Company’s Quarterly Report on Form 10-Q for the for the three months ended March 31, 2025 (the ‘10-Q’) was not filed with the Securities and Exchange Commission (the ‘SEC’) by the required due date of May 15, 2025.”
On this news, Zeo’s stock price fell $0.34 per share, or 9.91%, to close at $3.09 per share on May 30, 2025.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
- Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds - June 25, 2025
- WISeSat Signs a Service Agreement with Astrocast to Allow Access to Astrocast’s Operational Satellite Constellation - June 25, 2025
- Novartis announces expiration of Regulus Therapeutics tender offer - June 25, 2025
